Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study looks at hepatitis c Virus's hidden protein partners

NCT ID NCT02795403

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study aims to identify human proteins that stick to hepatitis C virus particles in patient blood samples. By understanding which proteins the virus uses to survive and spread, researchers hope to find new targets for future treatments. Ten adults with chronic hepatitis C each provided two large blood samples for analysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could reveal new targets for future hepatitis C treatments.
What could go wrong
This is a very small, early-stage study (10 participants) focused on basic biology, not a treatment trial. Findings may not lead to any new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Start date

Jan 2011

Finished

Jul 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult\> 18 and \<60 years * Infected with HCV genotype 1 HCV antibody positive. * positive viremia for more than 6 months * Viremia\> 106 IU / ml. * nonresponders to previous treatment and without antiviral treatment for 2 months. * For control samples: Patients responders to previous treatment and without antiviral treatment for 2 months. Exclusion Criteria: * Patient receiving or having received antiviral treatment within two months. * patient with against-indication for a blood sample of 150 ml * immunosuppressive therapy patient * Patient with liver disease other than hepatitis C. * Patients with cirrhosis. * patient with hepatocellular carcinoma. * Patients with one or more severe co-morbidities defined as: * Co-infection with HIV or HBV. * hematological malignancies changing or aplasia * Insulin-dependent diabetes * dialyzed chronic renal failure * Heart failure * Persons subject to legal protection or the subject of a safeguard measure of justice not affiliated with a social security scheme or not beneficiaries of such a scheme * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C

Contacts and locations

Locations

  • Service d'Hépato-Gastroentérologie Lyon Croix-Rousse Hospices Civils de Lyon

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.